Single Intramuscular Methylprednisolone dose in Asthma and Chronic Obstructive Pulmonary Disease Patients on Discharge.

In this pilot study we aimed to evaluate the safety of a single intramuscular methylprednisolone (IM) injection at the time of discharge as a replacement for oral steroid therapy for patients in our population with asthma or chronic obstructive pulmonary disease (COPD). This proof-of-concept, open label clinical trial without randomisation was conducted at the Pulmonary Department of Ziauddin Hospital and University, Karachi from January 2018 to March 2018. Patients discharged after in-hospital treatment for exacerbations of either asthma or COPD were recruited for this study. Intramuscular injection of methylprednisolone was administered to these patients who were then followed-up after one week and one month. During that period, information was collected of the patients' self-report of any unscheduled emergency room visit, blood sugar and blood pressure control, symptoms suggestive of thrush, increase gastric acidity and weight gain. For the data analysis, frequency and percentages were calculated with SPSS version 21. A total of 30 patients aged 52.83 ± 14.27 years were recruited for this pilot study. At one month follow-up, no unscheduled emergency room visits were observed in all of the study patients. Symptoms suggestive of oral thrush were recorded in only 2 (6.7%) patients and weight gain was reported by only 5 (16.7%). Controlled blood sugar and blood pressure was reported by all the patients. No incidence of nocturnal symptoms, awakening and dyspepsia were reported. A single dose of methylprednisolone injection without any obvious side effects over one month among patients with asthma and COPD demonstrated a safe strategy for them.